Nivolumab For The Treatment Of Classical Hodgkin Lymphoma ...
Based on the results of this phase I trial, nivolumab received Breakthrough Therapy Designation by the U.S. FDA for the and demonstrated remarkable clinical activity. Nivolumab was well tolerated and produced an unprecedented 87% response rate in a cohort of heavily pretreated patients. ... Visit Document
Study Of Nivolumab Given Sequentially With Ipilimumab In ...
Study of Nivolumab Given Sequentially With Ipilimumab in Subjects Trial Location Details. Facility: Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately ... Visit Document
PRO 140 - Wikipedia, The Free Encyclopedia
Development. PRO 140 is being developed by Cytodyn Inc. In May 2007, results from the phase I clinical trial of the drug demonstrated "potent, rapid, prolonged, dose-dependent, highly significant antiviral activity" for PRO 140. ... Read Article
Survival, Durable Tumor Remission, And Long-Term Safety In ...
Clinical trial information: NCT00730639. Corresponding author: Suzanne L. Topalian, MD, Department of Surgery, tients with advanced melanoma receiving nivolumab that was based on preliminary findings of durable tumor regression in these pa- ... Doc Retrieval
Trial Of Nivolumab Vs Therapy Of Investigator's Choice In ...
Bristol-Myers Squibb Investigators Study Director: Bristol-Myers Squibb Bristol-Myers Squibb More Information Additional Information: BMS Clinical Trial Information ... Access Document
Ipilimumab For Melanoma Treatment - Skin Cancer
Ipilimumab has been tested in multiple clinical trials for many years and appears to finally be on the verge of FDA approval, perhaps as early as 2010. That's certainly good news for patients with melanoma, who have few options once the disease spreads to other areas of the body. ... Read Article
CheckMate -141, A Pivotal Phase 3 Opdivo (nivolumab) Head And Neck Cancer Trial, Stopped Early
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today announced that a randomized Phase 3 study evaluating Opdivo (nivolumab) versus investigator’s choice in patients with recurrent or metastatic platinum-refractory squamous cell carcinoma of the head and neck (SCCHN) was stopped early because an assessment conducted by the independent Data Monitoring Committee (DMC ... Read News
Vedolizumab - Wikipedia, The Free Encyclopedia
Vedolizumab (trade name Entyvio) [23] [24] An additional clinical trial, GEMINI LTS (Long-term Safety), is still being run. [25] Nivolumab; Pembrolizumab; Tremelimumab; Urelumab; other: Bertilimumab; Zanolimumab; Mouse ("-limo-") Afelimomab; Elsilimomab; ... Read Article
List Of Phase III Cancer Clinical Trials 2015 - Wikipedia ...
List of Phase III Cancer Clinical Trials 2015. compound cancer type reference companies involved; Abemaciclib: breast cancer, lung cancer Nivolumab: non-small cell lung cancer: Brystol-Myers Squibb: Obinutuzumab + chlorambucil: cell lung carcinoma: ... Read Article
Phase I/II Opdivo (nivolumab) Trial Shows Bristol-Myers ...
Phase I/II Opdivo (nivolumab) Trial Shows Bristol-Myers Squibb’s PD-1 Immune Checkpoint Across the clinical trial experience in 691 patients with solid tumors, fatal immune-mediated pneumonitis occurred in 0.7% (5/691) ... Read Full Source
Mastering Oncology Immunotherapy Clinical Trials: The Smaller ...
Nivolumab (OPDIVO®; BMS division is comprised of more than 300 oncology clinical trial specialists across all functional areas. Headquartered in Research Triangle Park, NC, and with active oncology work in 45 ... Retrieve Content
Five Prime Therapeutics' Phase 1a/1b Trial Of FPA008 And ...
Five Prime Therapeutics' Phase 1a/1b Trial of FPA008 and OPDIVO (nivolumab) Featured as a Trial-in-Progress at the CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference SOUTH SAN FRANCISCO, Sept. 18, in six tumor types in a Phase 1a/1b clinical trial. Five ... Retrieve Here
FDA Approves Nivolumab (Opdivo) For NSCLC
Important clinical trial when results first became available in late December 2014,” said Richard The trial that led to the approval was an open-label, FDA Approves Nivolumab (Opdivo) for NSCLC. Published on Cancer Network ... Content Retrieval
Nivolumab, Pembrolizumab, Ramucirumab Not Covered
60DayNotice_1505-01 ramucirumab & nivolumab . Group Health Cooperative . 12400 E Marginal Way South . AMB-2 . Seattle, WA 98168 . Not covered due to insufficient evidence to show that these medications provide better clinical outcomes In one trial, patients were ... Read Content
NRG GY003: Phase II Randomized Trial Of Nivolumab With Or ...
NRG GY003: Phase II Randomized Trial of Nivolumab with or without Ipilimumab in Patients with Persistent or Recurrent Epithelial Ovarian, MRI or caliper measurement by clinical exam; or ≥ 20 mm when measured by chest x-ray. ... Access Doc
Development Status Of ONO-4538(nivolumab)
Development status of ONO-4538(nivolumab) Planned presentation about nivolumab in ASCO 2015：overseas clinical trial . 11/7 Non small cell lung cancer Phase II studies of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients with advanced squamous (sq) or non- ... Access Full Source
Immunotherapy For Small Cell Lung Cancer
Cancer — nivolumab was recently approved for the treatment, in the third line setting, for squamous cell lung cancer, and has received NCCN designation to two agents – one was nivolumab, and that clinical trial was very early phase, ... Doc Viewer
SOUTHERN ARIZONA CLINICAL TRIALS - Phoenix - Tuscon
SOUTHERN ARIZONA CLINICAL TRIALS. Trial listing current as of 9/2014. Bladder Cancer . PDL1 for Met Bladder Cancer. USON 13227: A Phase II, An Open-Label, Randomized Phase III Trial of Nivolumab Versus Investigator’s Choice Chemotherapy as . First-Line Therapy for Stage IIIB/IV or ... Read Document
Nivolumab with ipilimumab for advanced melanoma – first line SUMMARY NIHR HSC ID: 8877 human anti-CTLA-4 monoclonal antibody. In clinical trials1, nivolumab was administered via intravenous (IV) Trial CheckMate 067, NCT01844505, CA209-067, ... Document Retrieval
CheckMate 067: Phase 3 trial Of nivolumab In Melanoma - YouTube
University of Nebraska Medical Center, Omaha, NE, discusses the phase 3 CheckMate 067 trial of nivolumab alone or combined with ipilimumab versus ipilimumab alone in treatment-naive patients with advanced melanoma. ... View Video
East Coast Biotech Roundup: Editas, Hep C, Akashi, Tarveda & More
January is just about over, and for biotech investors, that’s a good thing. The Nasdaq Biotechnology Index (NASDAQ: IBB) has plummeted more than 22 percent in January. Thursday alone the index fell more than 3.6 percent without any clear negative catalyst (see this Fortune article), prompting a series of notes from sell-side analysts trying to […] ... Read News
LONDON CANCER ALLIANCE - CLINICAL TRIALS
LONDON CANCER ALLIANCE - CLINICAL TRIALS Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an ... Content Retrieval
BMY - Isigrp.com
BMY . Abstract #8112 . Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients (pts) In a phase I clinical trial, 411 pts received MK-3475 2 mg/kg Q3W, 10 mg/kg Q3W, or 10 mg/kg Q2W. Response was assessed every 12 wk by RECIST 1.1 by ... View This Document
Opdivo (nivolumab) + Yervoy (ipilimumab) Regimen Receives ...
Bristol-Myers Squibb’s Opdivo (nivolumab) + Yervoy (ipilimumab) transition from a clinical trial. More information about our reimbursement support services can be obtained by calling 1-800-861-0048 or by visiting www.bmsaccesssupport.com. ... Fetch Full Source
Nivolumab In Patients With Relapsed Or Refractory Hodgkin ...
• Appraise recent clinical trial data on the use of immune checkpoint inhibition for patients with relapsed or refractory HL. nivolumab in Patients with relapsed or refractory Hodgkin Lymphoma ... Retrieve Document
An Open Label Randomized Phase III trial Of nivolumab Or ...
An open label randomized Phase III trial of nivolumab or nivolumab plus ipilimumab vs platinum doublet chemotherapy (PT-DC) in encouraging clinical benefit across multiple tumor types. Two randomized Phase III trials demonstrated superior ... Document Viewer
No comments:
Post a Comment